Inhibition of Proliferation and Induction of Apoptosis in Multiple Myeloma Cell Lines by CD137 Ligand Signaling

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Gullo, Charles ^a   Koh, Liang Kai ^b   Pang, Wan Lu ^b   Ho, Kian Tong ^a   Tan, Shi Hao ^b   Schwarz, Herbert ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; GROWTH INHIBITION; IMMOBILIZED CELL; IN VITRO STUDY; MULTIPLE MYELOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

4-1BB LIGAND; ANTIGENS, CD137; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-2; INTERLEUKIN-6; LYMPHOMA; MULTIPLE MYELOMA; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77956539667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010845     Document Type: Article

References (50)

1. Selina SK (2003) Plasma Cells and Multiple Myeloma. Immunological Reviews 194: 5-7.
2. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351: 1860-1873.
3. Bensinger WI (2004) The current status of hematopoietic stem cell transplantation for multiple myeloma. Clin Adv Hematol Oncol 2: 46-52.
4. Rajkumar SV, Kyle RA (2005) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80: 1371-1382.
5. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
6. Bringhen S, Avonto I, Magarotto V, Boccadoro M, Palumbo A (2006) Investigational treatments for multiple myeloma. Expert Opin Investig Drugs 15: 1565-1582.
7. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC (2008) Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma 49: 1238-1245.
8. Sica G, Chen L (2000) Modulation of the immune response through 4-1BB. Adv Exp Med Biol 465: 355-362.
9. Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3: 609-620.
10. Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68.
11. Schwarz H (2005) Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol 77: 281-286.
12. Langstein J, Michel J, Fritsche J, Kreutz M, Andreesen R, et al. (1998) CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 160: 2488-2494.
13. Langstein J, Michel J, Schwarz H (1999) CD137 induces proliferation and endomitosis in monocytes. Blood 94: 3161-3168.
14. Langstein J, Becke FM, Sollner L, Krause G, Brockhoff G, et al. (2000) Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation. Biochem Biophys Res Commun 273: 117-122.
15. Langstein J, Schwarz H (1999) Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol 65: 829-833.
16. Ju SW, Ju SG, Wang FM, Gu ZJ, Qiu YH, et al. (2003) A functional anti-human 4-1BB ligand monoclonal antibody that enhances proliferation of monocytes by reverse signaling of 4-1BBL. Hybrid Hybridomics 22: 333-338.
17. Drenkard D, Becke FM, Langstein J, Spruss T, Kunz-Schughart LA, et al. (2007) CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J 21: 456-463.
18. Laderach D, Wesa A, Galy A (2003) 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol 226: 37-44.
19. Lippert U, Zachmann K, Ferrari DM, Schwarz H, Brunner E, et al. (2008) CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol 38: 1024-1032.
20. Jiang D, Yue PS, Drenkard D, Schwarz H (2008) Induction of proliferation and monocytic differentiation of human CD34+ cells by CD137 ligand signaling. Stem Cells 26: 2372-2381.
21. Jiang D, Chen Y, Schwarz H (2008) CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol 181: 3923-3932.
22. Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H (2002) CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 72: 35-42.
23. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA (2003) Expression of CD137 (4-1BB) on human follicular dendritic cells. Scand J Immunol 57: 305-310.
24. Schwarz H, Blanco FJ, von KJ, Valbracht J, Lotz M (1996) ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood 87: 2839-2845.
25. Hwang WY, Gullo CA, Shen J, Poh CK, Tham SC, et al. (2006) Decoupling of normal CD40/interleukin-4 immunoglobulin heavy chain switch signal leads to genomic instability in SGH-MM5 and RPMI 8226 multiple myeloma cell lines. Leukemia 20: 715-723.
26. Jung HW, Choi SW, Choi JI, Kwon BS (2004) Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 36: 13-22.
27. Zhou Z, Kim S, Hurtado J, Lee ZH, Kim KK, et al. (1995) Characterization of human homologue of 4-1BB and its ligand. Immunol Lett 45: 67-73.
28. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, et al. (1994) 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 24: 367-374.
29. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, et al. (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354.
30. Kline M, Donovan K, Wellik L, Lust C, Jin W, et al. (2007) Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 31: 591- 598.
31. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, et al. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85.
32. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A (1995) Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85: 487-494.
33. Lauta VM (2003) A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440-2452.
34. Chen W, Frank ME, Jin W, Wahl SM (2001) TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14: 715-725.
35. Kabelitz D, Pohl T, Pechhold K (1993) Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 14: 338-339.
36. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB (2000) Assay for redox-sensitive transcription factor. Methods Enzymol 319: 585-602.
37. Daniel PT, Oettinger U, Mapara MY, Bommert K, Bargou R, et al. (1997) Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Eur J Immunol 27: 1029-1034.
38. Berard M, Casamayor-Palleja M, Billian G, Bella C, Mondiere P, et al. (1999) Activation sensitizes human memory B cells to B-cell receptor-induced apoptosis. Immunology 98: 47-54.
39. Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, et al. (2002) Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 100: 217-223.
40. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305: 626-629.
41. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, et al. (1991) Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 51: 6250-6253.
42. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, et al. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636.
43. Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, et al. (2004) GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103: 3474-3479.
44. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, et al. (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64: 2846-2852.
45. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, et al. (2005) Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 65: 8331-8338.
46. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, et al. (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25: 876-883.
47. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, et al. (1994) Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83: 2787-2794.
48. Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, et al. (2002) Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 100: 217-223.
49. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
50. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.